Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin- Tazobactam Breakpoints Against Pseudomonas aeruginosa

摘要

TO the Editor—In January 2023, the Clinical and Laboratory Standards Institute (CLSI) revised the piperacillin-tazobactam (PTZ) interpretive criteria against Pseudomonas aeruginosa that were previously updated in 2012 (Table 1). As described elsewhere, new information from any of 3 primary data sources (ie, epidemiologic cutoff values [ECVs], pharmacokinetic-pharmacodynamic [PK/PD] data, and clinical outcomes data) generally trigger a reinvestigation into whether a revision of breakpoints for a given agent is warranted. The CLSI believes that all 3 of these categories are necessary in determining optimal susceptibility interpretive criteria. Herein, we review data that informed the 2023 breakpoint revision.